Community Preparedness for Outbreak Response and Readiness for Ebola Vaccination in Liberia

May 24, 2023 updated by: UL-PIRE Africa Center

Community Preparedness for Outbreak Response and Readiness for ZEBOV Vaccination in Liberia

This community-based mixed methods study intends to identify, explore, and assess the determinants of community preparedness for outbreak situations, including acceptance for Ebola vaccines.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

This community-based study intends to identify, explore, and assess the determinants of community preparedness for outbreak situations and acceptance for the administration of Ebola vaccination. The investigators will conduct an anthropologically driven mixed methods study design that comprises both qualitative and quantitative research methods for the successful implementation of this community-based study. The investigators will conduct structured interviews with community members and local responders to broadly assess and understand the perspectives regarding appropriate strategies previously employed to effectively support community preparedness during outbreak response and also to broadly access and understand appropriate strategies previously employed to effectively support community acceptance for Ebola vaccines, respectively. Learning from the experiences of local voices produces globally emergent systems that are trusted, reliable and sustainable.

Study Type

Observational

Enrollment (Estimated)

1500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Liberia
    • Montserrado County
      • Monrovia, Montserrado County, Liberia, 1000
        • Montserrado, Margibi and Lofa Counties
        • Contact:
        • Contact:
        • Principal Investigator:
          • Stephen B Kennedy, MD, MPH

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Health adults (males and females)

Description

Inclusion Criteria:

  • Adults
  • Community Leaders
  • Community Members
  • Reside in 1 of 3 highly prevalent counties
  • Participated actively in EVD outbreaks related activities
  • Documented roles recognized by the Incident Management System

Exclusion Criteria:

  • Not Adults
  • Does not reside in any of the 3 highly prevalent counties
  • Did not actively participate in the EVD outbreak response related activities
  • Roles not documented by the Incident Management System

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Cluster 1
Communities highly affected and impacted by EVD
Behavioral: Community Clusters
Assessment of the determinants for community preparedness to EVD outbreaks and acceptance of EVD vaccines.
Other Names:
  • Community Cohorts
Cluster 2
Communities not highly affected and impacted by EVD
Behavioral: Community Clusters
Assessment of the determinants for community preparedness to EVD outbreaks and acceptance of EVD vaccines.
Other Names:
  • Community Cohorts
Cluster 3
Communities receptive to EVD vaccination
Behavioral: Community Clusters
Assessment of the determinants for community preparedness to EVD outbreaks and acceptance of EVD vaccines.
Other Names:
  • Community Cohorts
Cluster 4
Communities resistance to EVD vaccination
Behavioral: Community Clusters
Assessment of the determinants for community preparedness to EVD outbreaks and acceptance of EVD vaccines.
Other Names:
  • Community Cohorts

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Measure #1
Time Frame: 2 Years
Assess Community Preparedness with the Resiliency Scale
2 Years
Measure #2
Time Frame: 2 Years
Assess Community Acceptance of EVD Vaccine with the Resiliency Scale
2 Years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Measure #3
Time Frame: 2 Years
Assess Roles of Community Leaders with the Resiliency Scale
2 Years
Measure #4
Time Frame: 2 Years
Assess Roles of Formal and Informal Community Structures with the Resiliency Scale
2 Years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

UL-PIRE Africa Center

Collaborators

West African Consortium for Clinical Research on Epidemic Pathogens (WAC-CREP)

Investigators

  • Principal Investigator: Stephen B Kennedy, MD, MPH, UL-PIRE Africa Center, University of Liberia

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 1, 2023

Primary Completion (Estimated)

April 30, 2025

Study Completion (Estimated)

April 30, 2025

Study Registration Dates

First Submitted

April 27, 2023

First Submitted That Met QC Criteria

May 24, 2023

First Posted (Actual)

June 5, 2023

Study Record Updates

Last Update Posted (Actual)

June 5, 2023

Last Update Submitted That Met QC Criteria

May 24, 2023

Last Verified

May 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MISP 101054

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Ebola Virus Disease

Clinical Trials on Community Clusters

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe